Dorsey & Whitney Trust CO LLC Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Dorsey & Whitney Trust CO LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,093 shares of the medical research company’s stock after selling 865 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Edwards Lifesciences were worth $377,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in EW. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC boosted its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.6 %

EW stock opened at $68.49 on Tuesday. The company has a market capitalization of $40.26 billion, a PE ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company’s 50 day moving average price is $72.14 and its two-hundred day moving average price is $70.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,303 shares of company stock valued at $3,255,356. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. Citigroup increased their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.